Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
JAMA Surg. 2019 Sep 1;154(9):e192172. doi: 10.1001/jamasurg.2019.2172. Epub 2019 Sep 18.
Previously, it was shown in patients with low rectal cancer that a short-axis (SA) lateral node size of 7 mm or greater on primary magnetic resonance imaging (MRI) resulted in a high lateral local recurrence (LLR) rate after chemoradiotherapy or radiotherapy ([C]RT) with total mesorectal excision (TME) and that this risk was lowered by a lateral lymph node dissection (LLND). The role of restaging MRI after (C)RT with regard to LLR risk and which specific patients might benefit from an LLND is not fully understood.
To determine the factors on primary and restaging MRI that are associated with LLR in low rectal cancer after (C)RT and to formulate specific guidelines on which patients might benefit from an LLND.
DESIGN, SETTING, AND PARTICIPANTS: In this retrospective, multicenter, pooled cohort study, patients who underwent surgery for cT3 or cT4 low rectal cancer with a curative intent from 12 centers in 7 countries from January 2009 to December 2013 were included. All patients' MRIs were rereviewed according to a standardized protocol, with specific attention to lateral nodal features. The original cohort included 1216 patients. For this study, patients who underwent (C)RT and had a restaging MRI were selected, leaving 741 for analyses across 10 institutions, including 651 who underwent (C)RT with TME and 90 who underwent (C)RT with TME and LLND.
The main purpose was to identify the factors on primary and restaging MRI associated with LLR after (C)RT with TME. Whether high-risk patients might benefit in terms of LLR reduction from an LLND was also studied.
Of the 741 included patients, 480 (64.8%) were male, and the mean (SD) age was 60.4 (12.0) years. An SA lateral node size of 7 mm or greater on primary MRI resulted in a 5-year LLR rate of 17.9% after (C)RT with TME. At 3 years, there were no LLRs in 28 patients (29.2%) with lateral nodes that were 4 mm or less on restaging MRI. Nodes that were 7 mm or greater on primary MRI and greater than 4 mm on restaging MRI in the internal iliac compartment resulted in a 5-year LLR rate of 52.3%, significantly higher compared with nodes in the obturator compartment of that size (9.5%; hazard ratio, 5.8; 95% CI, 1.6-21.3; P = .003). Compared with (C)RT with TME alone, treatment with (C)RT with TME and LLND in these unresponsive internal nodes resulted in a significantly lower LLR rate of 8.7% (hazard ratio, 6.2; 95% CI, 1.4-28.5; P = .007).
Restaging MRI is important in clinical decision making in lateral nodal disease. In patients with shrinkage of lateral nodes from an SA node size of 7 mm or greater on primary MRI to an SA node size of 4 mm or less on restaging MRI, which occurs in about 30% of cases, LLND can be avoided. However, persistently enlarged nodes in the internal iliac compartment indicate an extremely high risk of LLR, and an LLND lowered LLR in these cases.
先前的研究表明,对于低位直肠癌患者,原发磁共振成像(MRI)上短轴(SA)侧方淋巴结大小≥7mm 与放化疗后全直肠系膜切除(TME)联合侧方淋巴结清扫(LLND)的化放疗(C)后侧方局部复发(LLR)率较高有关。放化疗后 C)后 LLR 风险与侧方淋巴结再分期 MRI 之间的关系以及哪些特定患者可能从 LLND 中获益尚未完全了解。
确定原发和再分期 MRI 上与低位直肠癌 C)后化放疗后 LLR 相关的因素,并制定具体的指南,确定哪些患者可能从 LLND 中获益。
设计、地点和参与者:在这项回顾性、多中心、汇集队列研究中,纳入了 2009 年 1 月至 2013 年 12 月期间来自 7 个国家的 12 个中心接受根治性 intent cT3 或 cT4 低位直肠癌手术的患者。所有患者的 MRI 均根据标准化协议进行了重新评估,特别注意侧方淋巴结的特征。原始队列包括 1216 例患者。本研究中,选择了接受 C)并进行了侧方淋巴结再分期 MRI 的患者,其中 10 个机构的 741 例患者纳入分析,包括 651 例接受 C)并接受 TME 的患者和 90 例接受 C)并接受 TME 和 LLND 的患者。
主要目的是确定与 TME 后 C)相关的原发和再分期 MRI 上与 LLR 相关的因素。还研究了高危患者是否可能从 LLND 中降低 LLR 获益。
在纳入的 741 例患者中,480 例(64.8%)为男性,平均(SD)年龄为 60.4(12.0)岁。原发 MRI 上侧方淋巴结短轴(SA)大小≥7mm 的患者,在接受 TME 联合 C)治疗后 5 年的 LLR 率为 17.9%。在 3 年内,在侧方淋巴结再分期 MRI 上淋巴结短轴(SA)大小为 4mm 或更小的 28 例患者中,无 LLR。原发 MRI 上为 7mm 或更大且在内部髂骨间隙的再分期 MRI 上大于 4mm 的淋巴结,5 年 LLR 率为 52.3%,显著高于大小为该尺寸的闭孔间隙中的淋巴结(9.5%;风险比,5.8;95%CI,1.6-21.3;P=0.003)。与单独接受 C)并接受 TME 治疗相比,在这些无反应性的内部淋巴结中联合接受 C)并接受 TME 和 LLND 治疗,LRR 率显著降低,为 8.7%(风险比,6.2;95%CI,1.4-28.5;P=0.007)。
侧方淋巴结疾病的临床决策中,侧方淋巴结再分期 MRI 很重要。在原发 MRI 上侧方淋巴结短轴(SA)大小≥7mm 缩小至再分期 MRI 上的短轴(SA)大小为 4mm 或更小的情况下,大约 30%的患者可以避免 LLND。然而,内髂骨间隙中持续增大的淋巴结提示 LLR 风险极高,LLND 可降低这些情况下的 LLR。